Recombinant Mouse Transmembrane protein 92 (Tmem92)

What is the structural classification of mouse TMEM92?

TMEM92 belongs to the transmembrane (TMEM) family of proteins that span the entire width of lipid bilayers. While specific structural details of mouse TMEM92 continue to be characterized, research indicates it functions as an adaptor for E3 ubiquitin ligase, supporting the degradation of β-catenin and E-cadherin . For researchers initiating TMEM92 studies, it is advisable to begin with computational predictions of membrane topology using algorithms such as TMHMM or Phobius to identify transmembrane domains, followed by structural validation through techniques like circular dichroism or, ideally, X-ray crystallography for detailed structural analysis.

What are the recommended expression systems for producing recombinant mouse TMEM92?

For optimal recombinant mouse TMEM92 production, mammalian expression systems (particularly HEK293 or CHO cells) typically yield proteins with proper folding and post-translational modifications. The methodological approach should include:

• Cloning the full-length mouse TMEM92 cDNA into a mammalian expression vector containing appropriate tags (His, FLAG, or GST) to facilitate purification

• Transfection of host cells using lipofection or electroporation

• Selection of stable transfectants using appropriate antibiotics

• Verification of expression via Western blotting

• Purification using affinity chromatography based on the chosen tag

For functional studies, it's critical to confirm that the recombinant protein retains native activity through functional assays examining its interaction with known binding partners.

What detection methods are most effective for analyzing mouse TMEM92 expression?

Multiple complementary techniques should be employed for comprehensive TMEM92 detection:

• Protein level detection: Western blotting with validated anti-TMEM92 antibodies remains the gold standard. For quantitative analysis, researchers should consider using ELISA or mass spectrometry-based approaches.

• Transcriptional analysis: qRT-PCR for TMEM92 mRNA quantification, with careful selection of reference genes for normalization .

• Localization studies: Immunofluorescence or immunohistochemistry using confocal microscopy to visualize cellular distribution.

When analyzing TMEM92 in mouse models, careful validation of antibody specificity is essential, as cross-reactivity can lead to misleading results.

How is mouse TMEM92 regulated at the transcriptional level?

The transcriptional regulation of TMEM92 involves multiple mechanisms:

• MicroRNA regulation: Evidence shows that miR-23a and miR-24 overexpression can lead to gene silencing of TMEM92, resulting in mesothelial cell integration of pancreatic cancer . For studying such regulation, researchers should employ luciferase reporter assays with wild-type and mutated TMEM92 3'UTR constructs.

• Promoter analysis: Computational identification of transcription factor binding sites followed by ChIP assays can help identify key transcriptional regulators.

A methodological approach should include both in silico analysis of the promoter region and experimental validation through reporter assays and mutation studies.

What experimental models are most appropriate for studying TMEM92's role in cancer immune evasion?

For investigating TMEM92's immunomodulatory functions:

• In vitro models: Co-culture systems with cancer cells (expressing varying levels of TMEM92) and peripheral blood mononuclear cells (PBMCs) provide a controlled environment to study immune interactions .

• Ex vivo models: Patient-derived organoids expressing different levels of TMEM92 can be used with autologous immune cells.

• In vivo models: Syngeneic mouse models with TMEM92 knockout or overexpression, examined with comprehensive immune profiling.

Methodologically, researchers should combine these approaches with technologies like mass cytometry or single-cell RNA sequencing for detailed characterization of immune cell populations and their functional states in response to TMEM92 manipulation.

How can researchers effectively evaluate TMEM92's impact on immune checkpoint inhibitor efficacy?

To assess TMEM92's influence on immunotherapy response:

• In vitro approach: SW1990 or Capan-2 pancreatic cancer cells with TMEM92 overexpression or knockdown should be co-cultured with PBMCs in the presence of PD-1 blocking antibodies. Cell viability can be measured using MTS assays to quantify the impact of TMEM92 on treatment efficacy .

• In vivo methodology:

  • Establish syngeneic mouse tumor models with TMEM92 overexpression/knockdown

  • Treat with immune checkpoint inhibitors (anti-PD-1/PD-L1)

  • Monitor tumor growth, survival, and immune infiltration

  • Analyze tumor and immune cells by flow cytometry to assess T cell activation and exhaustion markers

• Mechanistic investigation: Examine PD-L1 expression levels in TMEM92-manipulated cells using both qRT-PCR and Western blotting to distinguish between transcriptional and post-transcriptional regulation .

Research has shown that TMEM92 overexpression can downregulate PD-L1 at both pre- and post-transcriptional levels in pancreatic cancer cells, potentially explaining diminished response to immune checkpoint blockade therapy .

What are the recommended methods for investigating the relationship between TMEM92 and tumor mutation burden (TMB)?

The relationship between TMEM92 and TMB can be methodically investigated through:

• Computational analysis: Using TCGA datasets to correlate TMEM92 expression with TMB scores across multiple tumor types.

• Experimental validation:

  • Generate isogenic cell lines with TMEM92 overexpression/knockdown

  • Perform whole-exome sequencing to determine mutation frequencies

  • Focus on prevalent mutations (e.g., KRAS, TP53 in pancreatic cancer)

• Clinical correlation: Stratify patient cohorts by TMEM92 expression and assess:

  • TMB status

  • Common genetic alterations

  • Response to immunotherapy

Research has demonstrated that high TMEM92 expression positively correlates with increased TMB (Spearman correlation: R = 0.31, p = 1.6e-4) and is associated with higher frequency of KRAS and TP53 mutations in pancreatic cancer .

What methodologies should be employed to study TMEM92's role in tumor cell proliferation?

A comprehensive approach to studying TMEM92's effect on proliferation includes:

• Gene manipulation:

  • Overexpression: Transfect cancer cells with TMEM92 expression plasmids

  • Knockdown: Use siRNA or CRISPR-Cas9 to reduce TMEM92 expression

  • Verify expression changes via qRT-PCR and Western blotting

• Proliferation assays:

  • Short-term: MTS/MTT assays for metabolic activity assessment

  • Long-term: Colony formation assays

  • Real-time: Live-cell imaging systems with automated cell counting

• Cell cycle analysis:

  • Flow cytometry with propidium iodide staining

  • Western blotting for cell cycle regulators

• Signaling pathway investigation:

  • Western blotting for key signaling molecules

  • Phosphoproteomics for comprehensive pathway mapping

Research has shown that TMEM92 can increase growth capability of pancreatic cancer cells, as demonstrated through MTS assays .

What experimental approaches are recommended for studying TMEM92's interaction with ubiquitin ligase machinery?

To investigate TMEM92's role as an adaptor for E3 ubiquitin ligase:

• Protein interaction studies:

  • Co-immunoprecipitation to identify binding partners

  • Proximity ligation assays for in situ interaction detection

  • Mass spectrometry following immunoprecipitation to identify the complete interactome

• Ubiquitination assays:

  • In vitro ubiquitination assays with recombinant proteins

  • Cell-based ubiquitination studies examining β-catenin and E-cadherin degradation

  • Ubiquitin chain typing using specific antibodies

• Domain mapping:

  • Generate deletion and point mutants of TMEM92

  • Perform interaction assays to identify critical binding regions

  • Structural modeling of interactions

• Functional consequences:

  • Monitor target protein half-life with cycloheximide chase assays

  • Examine pathway activation (e.g., Wnt pathway for β-catenin degradation)

This methodological approach will help elucidate TMEM92's precise role in the ubiquitin-proteasome system and its downstream effects on cellular processes.

How can mouse TMEM92 research be translated to human applications for prognostic biomarker development?

Developing TMEM92 as a prognostic biomarker requires a systematic translational approach:

• Cross-species validation:

  • Compare mouse and human TMEM92 sequence homology and expression patterns

  • Validate functional conservation through parallel experiments in mouse and human cells

• Biomarker development pipeline:

  • Retrospective analysis: Correlate TMEM92 expression with survival outcomes in patient cohorts

  • Multivariate analysis: Develop nomogram models that incorporate TMEM92 with established clinicopathological factors

  • Validation: Test in independent patient cohorts

• Standardization:

  • Establish reproducible detection methods for clinical settings

  • Define appropriate cut-off values for high versus low expression

What methodological approaches should be used to investigate TMEM92's role in tumor microenvironment modulation?

A comprehensive analysis of TMEM92's impact on tumor microenvironment requires:

• Cell population analysis:

  • Multiplex immunohistochemistry to visualize immune cell distribution

  • Flow cytometry for quantitative immune profiling

  • Single-cell RNA sequencing for detailed cell type identification and state characterization

• Functional studies:

  • Ex vivo tissue slice cultures to maintain spatial organization

  • 3D co-culture systems with varying TMEM92 expression levels

  • Cytokine profiling to assess secretome changes

• Bioinformatic approaches:

  • Deconvolution of bulk transcriptomic data using algorithms like CIBERSORT to quantify immune cell fractions

  • Gene co-expression network analysis to identify TMEM92-associated gene modules

  • Molecular Complex Detection (MCODE) algorithm to identify hub genes in immune response networks

Research has identified TMEM92 as a core gene within immune-resistance gene signature networks in pancreatic cancer, providing insights into its role in shaping an immunosuppressive tumor microenvironment .

What methodologies are recommended for developing targeted therapeutics against TMEM92?

The development of TMEM92-targeted interventions should follow a structured approach:

• Target validation:

  • Genetic approaches: CRISPR/Cas9 knockout or RNA interference

  • Pharmacological approaches: Small molecule screening

  • Confirmation in multiple cell lines and animal models

• Therapeutic development strategies:

  • Small molecule inhibitors targeting protein-protein interactions

  • Antibody-based approaches for accessible epitopes

  • Gene therapy approaches (siRNA, antisense oligonucleotides)

  • Proteolysis-targeting chimeras (PROTACs) for targeted degradation

• Combinatorial approaches:

  • Combining TMEM92 inhibition with immune checkpoint blockade

  • Synergistic targeting of TMEM92 and other immune-related pathways

• Prediction of responders:

  • Biomarker development for patient stratification

  • Generation of predictive algorithms based on multiple parameters

The potential of TMEM92 as a therapeutic target is supported by findings that TMEM92 inhibition could enhance the efficacy of immune checkpoint blockade therapy .

What are the current methodological challenges in studying TMEM92's impact on epithelial-mesenchymal transition?

Investigating TMEM92's role in epithelial-mesenchymal transition (EMT) requires addressing several methodological challenges:

• Model selection considerations:

  • 2D versus 3D culture systems for capturing EMT dynamics

  • Appropriate cell lines that maintain EMT plasticity

  • Animal models that recapitulate human disease progression

• Measurement approaches:

  • Morphological assessment: Phase-contrast microscopy, immunofluorescence

  • Protein markers: E-cadherin, N-cadherin, Vimentin, Snail, ZEB1/2

  • Functional assays: Migration, invasion, anoikis resistance

• Dynamic analysis:

  • Live cell imaging with fluorescent reporter systems

  • Temporal transcriptomic and proteomic profiling

  • Mathematical modeling of state transitions

• Context dependency:

  • Microenvironmental factors influencing EMT

  • Cell-cell and cell-matrix interactions

Research has indicated that TMEM92 depletion can downregulate N-cadherin, Vimentin, and Snail levels, resulting in EMT inactivation, suggesting its important role in this process .